AURKA and cancer: In an analysis of a highly specific AURKA inhibitor LY3295668 in 560 cancer cell lines, NB was among the most sensitive tumour type tested, with MYC/MYCN amplification identified as among the strongest predictors of sensitivity to this agent (Figure 2).